SSADH deficiency in an adult
Venturing outside of the diagnostic box and inside of the registry In rare diseases, the advent of potential therapies spurs early diagnosis, natural history studies, and the creation of patient registries. Succinic semialdehyde dehydrogenase (SSADH) deficiency is a relatively recently described autosomal recessive organic aciduria that is due to an inborn error of the second and final step of g-aminobutyric acid metabolism. 1 The presence of g-hydroxybutyric acid in the urine is suggestive of a diagnosis of SSADH deficiency, which may then be confirmed either by direct measurement of the activity of the enzyme or by sequencing of the ALDH5A1 gene. 2, 3 The clinical manifestations of SSADH deficiency reflect the involvement of the CNS and are characterized by psychomotor retardation, childhood-onset hypotonia, and ataxia. Seizures occur in more than 50% of affected individuals. Hyperkinetic behavior, aggression, self-injurious behaviors, hallucinations, and sleep disturbances may occur in nearly half of all patients. Basal ganglia signs such as choreoathetosis, dystonia, and myoclonus occur in a few individuals with earlier onset or more severe disease. 2, 3 The MRI is contributory when it shows a pallidodentatoluysian pattern: increased T2-weighted signal involving the globi pallidi bilaterally and symmetrically, the cerebellar dentate nuclei, and the subthalamic nuclei. 4 Other imaging findings are nonspecific, including T2 hyperintensities of subcortical white matter and brainstem, cerebral atrophy, cerebellar atrophy, and delayed myelination. 5 Involvement beyond the CNS, however, has not been described.
Given the clinical presentation, diagnosis would be expected relatively early in life, if a comprehensive evaluation that includes measurement of urine organic acids is undertaken. 6 However, as SSADH deficiency was discovered only 3 decades ago, it could be the etiology of an otherwise undiagnosed syndrome of neuropsychological impairment in adult patients with onset in childhood. Indeed, in this issue of Neurology ® , Lapalme-Remis et al. 7 report the history of an adult man with intellectual disability and epilepsy who, in his sixth decade, developed increasing difficulties with control of seizures and progressive encephalopathy. An elevated serum ammonia level led his astute clinicians to consider an inborn error of metabolism, and SSADH deficiency was confirmed in the patient at 62 years of age; the patient expired the following year.
As part of their report, the authors analyzed the database of the SSADH registry, established in 2001, specifically for the clinical features of adult patients. While some 450 patients with SSADH deficiency have been reported, 3 this rare disease registry contains clinical data for 112 affected individuals. Although the vast majority of the registered patients were diagnosed by 5 years of age, a few diagnoses were confirmed in late childhood or adolescence, and 3 patients (including the reported patient) were diagnosed during adulthood. At the time of this analysis, 40 of the registered patients were 18 years of age or older, and 25 members of this group had additional data submitted during adulthood as part of a periodic update of the registry, thus providing a snapshot of the SSADH deficiency phenotype in adult patients. Importantly, 60% of these patients had epilepsy, primarily generalized convulsions, absence seizures, and myoclonic events. EEG changes such as disorganized background slowing and generalized epileptiform discharges were present in two-thirds of the patients. In addition, neuropsychiatric symptoms were reported in more than half of the adult patients, including anxiety, obsessive-compulsive behaviors, hyperactivity, and sleep disturbances.
As pointed out by the authors, a limitation of this study is the cross-sectional analysis from this rare disease registry, with no uniform method of collection of longitudinal data (follow-up information on a subset of the registered patients was submitted only periodically by physicians or family members). While this report informs us that SSADH deficiency and other inborn errors of metabolism must be considered as possible etiologies of chronic neurodevelopmental disorders in adult patients, the trajectory of symptom evolution through the decades of an affected patient's life remains to be explored.
Patient registries, particularly those with a wide geographic scope, are a fundamental tool for acquiring information regarding phenotypic variation, disease progression, and response to management strategies for rare disorders and for facilitating patient recruitment for clinical trials. 8, 9 Registries that rely on the return of paper questionnaires or lengthy telephone calls are potentially affected by changes of address or telephone numbers as well as incomplete submission, thereby leading to partial acquisition of baseline and follow-up data. While not completely free from these drawbacks, Internet-based resources for communicating with patients, their families, and the principal clinicians, including reminder messages and Web-based data entry with branching logic that can individualize the questions posed depending on previous answers, are clear improvements over older survey methods. Electronic data capture (EDC) also facilitates the integration of laboratory, clinical neurophysiology, and imaging findings into the database. 10, 11 The use of EDC to continuously update records with longitudinal data and add information regarding new registrants, together with conversion of data acquired from "paper questionnaire registries" into a digital format, while certainly time consuming, should pay dividends for researchers studying SSADH deficiency as well as other rare disorders.
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